Fig 2: The effects of 1 on protein expression and phosphorylation levels of HIF-1α, VEGFR2 and its downstream signaling pathways of tumor tissue in 4T1 mammary carcinoma model. The levels of HIF-1α, p-VEGFR2, VEGFR2, p-Akt, Akt, p-mTOR, mTOR, p-FAK and FAK were determined by Western blots. (n = 3, means ± SEM are shown, * p < 0.05, ** p < 0.01, *** p < 0.001, compared with Saline treatment group; # p < 0.05, ## p < 0.01, ### p < 0.001, compared with Sorafenib treatment group).

Fig 3: The effects of 1 on protein expression and phosphorylation levels of VEGFR2 and its downstream signaling pathways in breast cancer cells. The levels of p-VEGFR2, VEGFR2, p-Akt, Akt, p-mTOR, mTOR, p-FAK and FAK were determined by Western blots. (n = 3, means ± SEM are shown, ** p < 0.01, *** p < 0.001, compared with control).

Fig 4: APLNR marks and immunomagnetically isolates cardiac progenitors. A. UMAP representation of the day 5 scRNA-seq dataset with superimposed colours representing different cell clusters. B. Top 10 DEGs in the cardiac progenitor cluster listed in descending order of logarithmic fold change. C. Top: Violin plot illustrating expression of cardiac progenitor surface markers in the dataset. Bottom: Single cell expression of the respective markers superimposed on the UMAP plot. D. Concurrent expression of KDR and PDGFRA in day 5 cells from the APLNR+ and APLNR− cell fraction. Data represented as mean ± SD from three independent differentiations for each hiPSC line. E. Representative KDR (Left) and PDGFRA (Right) flow cytometry scatter dot-plots to illustrate two KDR+ and PDGFRA+ cell populations. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

Fig 5: DCPIB inhibited VEGFR2 phosphorylation and its downstream signaling pathways. (A) Western blot analysis of p-VEGFR2 (Tyr1175), p-STAT3 and p-ERK levels in HUVECs treated with vehicle, VEGF165 and DCPIB for 10 min. Total VEGFR2, STAT3, ERK and β-actin were used as the loading control (n = 3~5). (B) Western blot analysis of RhoA and Cyclin D1 protein expression in HUVECs treated with vehicle, VEGF165 and DCPIB for 48 h. β-actin was used as the loading control (n = 4~5). (C–G) Quantitative analysis of p-VEGFR2, p-STAT3, p-ERK, RhoA and Cyclin D1 protein expression. *p < 0.05, **p < 0.01, ***p < 0.001.